Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q4 and full‑year 2025 results and a corporate update on March 9, 2026. Key clinical highlights: CRB-701 showed encouraging unconfirmed ORRs (HNSCC 47.6%, cervical 37.5%, bladder 55.6%) and has FDA Fast Track designations. CRB-913 showed 2.9% placebo‑adjusted weight loss at 14 days with favorable GI and neuropsychiatric profiles. Financially, Corbus completed a $75M public offering in Q4 2025 and held $163.3M cash, funding operations into 2028. Anticipated catalysts: CRB-701 and CRB-913 mid‑2026 data readouts; CRB-701 registrational discussions update in Q1 2026.

#CRBP Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/CRBP/corbus-pharmac...

Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q3 2025 results and a corporate update on Nov 12, 2025. The company presented CRB-701 dose-optimization data at ESMO 2025 showing ORRs at 3.6 mg/kg of 47.6% in HNSCC, 37.5% in cervical cancer, and 55.6% in bladder cancer. Corbus plans an FDA meeting in Q1 2026 and expects to start a Phase 2/3 registrational study by mid-2026; CRB-701 has Fast Track designation for HNSCC and metastatic cervical cancer.The company closed a public offering raising net proceeds of approximately $73.8M (total offering $75M), reporting $104.0M cash on 9/30/25 and stating runway into 2028. CRB-913 SAD/MAD readout and Phase 1b start expected by end of 2025. Q3 net loss was $23.3M versus $13.8M a year earlier.

#CRBP Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/CRBP/corbus-pharmac...

Corbus Pharmaceuticals Announces Pricing of Public Offering Corbus Pharmaceuticals (Nasdaq: CRBP) priced an underwritten public offering to raise approximately $75 million before underwriting discounts and expenses. The offering consists of 4,744,231 shares of common stock and pre-funded warrants to purchase 1,025,000 shares at $12.9999 each, with an exercise price of $0.0001 per share. Underwriters have a 30-day option for up to 865,384 additional shares. Closing is expected on or about November 3, 2025. Proceeds are intended to fund clinical development, working capital, and general corporate purposes.

#CRBP Corbus Pharmaceuticals Announces Pricing of Public Offering

www.stocktitan.net/news/CRBP/corbus-pharmac...

Corbus Pharmaceuticals Announces Proposed Public Offering Corbus Pharmaceuticals (Nasdaq: CRBP) announced on Oct 30, 2025 a proposed underwritten public offering of its common stock and, for certain investors, pre-funded warrants to purchase common stock. All securities will be sold by Corbus, and the offering is subject to market conditions with no assurance of completion, size, or terms.Corbus said it intends to use net proceeds to fund clinical development of its pipeline and for working capital and general corporate purposes. Jefferies and Piper Sandler are joint book-running managers, and underwriters may receive a 30-day option to buy up to an additional 15% of the shares. A registration statement became effective on Mar 20, 2024.

#CRBP Corbus Pharmaceuticals Announces Proposed Public Offering

www.stocktitan.net/news/CRBP/corbus-pharmac...

Leading Indicators, Wednesday October 22, 2025 – Crystal Equity Research

Small-cap stocks overbought with declining relative strength, Wed Oct 22nd - #STOK #SEED #REKR #ORKA #OCS #NXTC #EGAN #CRBP #LBRT #HQL #VCIC - More: crystalequityresearch.com/leading-indi... - #smallcap

News; ( NASDAQ: #CRBP ) Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 Corbus Pharmaceuticals (NASDAQ: CRBP) reported Phase 1/2 CRB-701 (SYS6002) data presented at ESMO25 showing clinical activity and a manageable safety profile.In response-evaluable patients dosed at 3.6 mg/kg, CRB-701 produced ORR 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in metastatic urothelial cancer. No dose-limiting toxicities were observed; Grade 3 treatment-related adverse events occurred in 18.0%, with no Grade 4/5 events and a 6.0% discontinuation rate. Data cutoff was September 1, 2025 (167 patients enrolled; 84 response-evaluable). The company plans an FDA meeting in 2025 and expects to initiate registrational studies by mid-2026.

#CRBP Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

www.stocktitan.net/news/CRBP/corbus-pharmac...

Most Searched, Wednesday October 15, 2025 – Crystal Equity Research

Most searched small-cap stocks, Wed Oct 15th - #VERI #SLNH #SES #LAC #SANA #LAES #TMQ #OMER #ONDS #NAK #USAR #RYOJ #NUAI #UAMY #NVTS #LGO #CRML #CRBP #ABAT - More: crystalequityresearch.com/most-searche... - #smallcap

Most Searched, Monday October 13, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Oct 13th - #UAMY #LAES #RR #AREC #RXRX #CRML #LAC #PMAX #STI #BYND #NAMM #WRD #ASPI #PTEN #PLUG #NVTS #LUNR #CRBP #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

FDA Fast-Tracks Revolutionary Nectin-4 ADC: Corbus Pharma's CRB-701 Shows Promise in Head & Neck Cancer Corbus's CRB-701 receives Fast Track designation for head & neck cancer treatment. Phase 1/2 dose optimization data to be presented at ESMO 2025. Second Fast Track after cervical cancer approval.

#CRBP FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

www.stocktitan.net/news/CRBP/fda-grants-fas...

Corbus Advances 3 Clinical Programs: Obesity Drug Trial Expands, Cancer Data Coming to ESMO Corbus advances obesity and cancer programs with $116M cash runway. Multiple data readouts expected in H2 2025, including ESMO presentation. Get full timeline.

#CRBP Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/CRBP/corbus-pharmac...

Corbus Cancer Drug Shows Promise: New Phase 1 Trial Combines Novel Nectin-4 ADC With Keytruda First patient receives CRB-701/Keytruda combination in Phase 1 trial targeting head and neck cancers. See latest safety and efficacy data from 100+ patient study.

#CRBP Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

www.stocktitan.net/news/CRBP/corbus-pharmac...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Thu Jun 5th - #TBCH #SRDX #RIGL #OCUL #NATR #ENTA #DRIO #CRBP #BWMN #AEHL #WGO #SQNS #ORN #GHM #DBD #CPF #BV - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Corbus Pharmaceuticals Appoints Industry Leader as Chair with 3 Major Clinical Readouts Coming Former Akari CEO Rachelle Jacques to lead Corbus board as company prepares for multiple clinical readouts in oncology and obesity programs. Learn timeline.

#CRBP Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

www.stocktitan.net/news/CRBP/corbus-pharmac...

Corbus Pharmaceuticals Secures FDA Fast Track for Cancer Drug as 3 Clinical Programs Hit Key Milestones Discover Corbus's latest clinical milestones: FDA Fast Track designation for CRB-701, promising trial data, and financial strength extending through 2027. See full results.

#CRBP Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/CRBP/corbus-pharmac...

Next-Gen Obesity Drug Shows 50x Better Safety Profile Than Previous Treatments as Clinical Trials Begin New obesity treatment CRB-913 demonstrates 50x lower brain exposure than earlier drugs, potentially offering safer weight loss option. Phase 1 trial now underway.

#CRBP Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

www.stocktitan.net/news/CRBP/corbus-pharmac...

Corbus Earnings: FDA Fast Track Status Powers $149M Cash Runway Through 2027 Corbus advances cancer treatment with FDA Fast Track designation while maintaining $149.1M cash position. New obesity program CRB-913 set for human trials in March 2025.

#CRBP Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/CRBP/corbus-pharmac...

Breakthrough Cancer Drug CRB-701 Delivers Powerful Results in Phase 1 Trial: Multiple Tumor Types Respond Corbus' CRB-701 demonstrates promising safety profile and broad anti-tumor activity in Phase 1 study, with notable responses in HNSCC, urothelial, and cervical cancers.

#CRBP CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

www.stocktitan.net/news/CRBP/crb-701-sys600...

Corbus Pharma's Cancer Drug CRB-701 Advances: Key Clinical Data Coming at ASCO-GU - Patient Enrollment Exceeds Targets Phase 1 trial data for CRB-701 in Nectin-4 positive tumors shows promising progress with expanded enrollment of 38 patients. Key findings to be revealed at ASCO-GU 2025.

#CRBP Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

www.stocktitan.net/news/CRBP/corbus-pharmac...

Corbus Pharmaceuticals to Present CRB-701 Cancer Drug Trial Data at ASCO GU 2025 Symposium Corbus' Phase 1 trial of CRB-701, a Nectin-4 targeting antibody-drug conjugate, successfully completed dose escalation across four levels in advanced solid tumor patients.

#CRBP Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

www.stocktitan.net/news/CRBP/corbus-pharmac...

Corbus Pharma Launches Phase 1 Trial for Novel Cancer Immunotherapy CRB-601 Corbus advances its promising TGFβ-targeting antibody CRB-601 into Phase 1 trials for solid tumors, following strong pre-clinical results in enhancing immunotherapy effectiveness.

#CRBP Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

#StockMarket #investing #stocks

www.stocktitan.net/news/CRBP/corbus-pharmac...

Corbus Pharma Secures FDA Fast Track Status for Cancer Drug CRB-701 | CRBP Stock News FDA grants Fast Track designation to Corbus Pharmaceuticals' CRB-701 for cervical cancer treatment. Phase 1 trial milestone reached with initial data expected Q1 2025.

#CRBP FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

#cancer #investing #StockMarket

www.stocktitan.net/news/CRBP/fda-grants-fas...

#CRBP Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference

www.stocktitan.net/news/CRBP/corbus-pharmac...

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#GOEV, #MPW, #UBER, #CRBP, #VRNA

#OptionFlow #OptionsTrading #Trading